{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:02:04Z","timestamp":1794013324530,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Whole genome sequencing (WGS) provides comprehensive, individualised cancer genomic information. However, routine tumour biopsies are formalin-fixed and paraffin-embedded (FFPE), damaging DNA, historically limiting their use in WGS. Here we analyse FFPE cancer WGS datasets from England\u2019s 100,000 Genomes Project, comparing 578 FFPE samples with 11,014 fresh frozen (FF) samples across multiple tumour types. We use an approach that characterises rather than discards artefacts. We identify three artefactual signatures, including one known (SBS57) and two previously uncharacterised (SBS FFPE, ID FFPE), and develop an \u201cFFPEImpact\u201d score that quantifies sample artefacts. Despite inferior sequencing quality, FFPE-derived data identifies clinically-actionable variants, mutational signatures and permits algorithmic stratification. Matched FF\/FFPE validation cohorts shows good concordance while acknowledging SBS, ID and copy-number artefacts. While FF-derived WGS data remains the gold standard, FFPE-samples can be used for WGS if required, using analytical advancements developed here, potentially democratising whole cancer genomics to many.<\/jats:p>","DOI":"10.1038\/s41467-024-51577-2","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T13:03:24Z","timestamp":1725455004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utility"],"prefix":"10.1038","volume":"15","author":[{"given":"Shadi","family":"Basyuni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1918-6266","authenticated-orcid":false,"given":"Laura","family":"Heskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-0596","authenticated-orcid":false,"given":"Andrea","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3840-4954","authenticated-orcid":false,"given":"Gene C. C.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Chmelova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-6049","authenticated-orcid":false,"given":"Giuseppe","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6774-3149","authenticated-orcid":false,"given":"Steven","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Grybowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7323-1596","authenticated-orcid":false,"given":"Greg","family":"Elgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Memari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Robbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Kingsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-4807","authenticated-orcid":false,"given":"Jean","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-8490","authenticated-orcid":false,"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PARTNER Trial Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Personalised Breast Cancer Program Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7880-0628","authenticated-orcid":false,"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-8211","authenticated-orcid":false,"given":"Matthew A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6381-3664","authenticated-orcid":false,"given":"Helen R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-1727","authenticated-orcid":false,"given":"Serena","family":"Nik-Zainal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"51577_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","volume":"15","author":"MF Berger","year":"2018","unstructured":"Berger, M. F. & Mardis, E. R. The emerging clinical relevance of genomics in cancer medicine. Nat. Rev. Clin. Oncol. 15, 353\u2013365 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51577_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jmoldx.2013.10.002","volume":"16","author":"CE Cottrell","year":"2014","unstructured":"Cottrell, C. E. et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J. Mol. Diagn. 16, 89\u2013105 (2014).","journal-title":"J. Mol. Diagn."},{"key":"51577_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jmoldx.2013.08.004","volume":"16","author":"CC Pritchard","year":"2014","unstructured":"Pritchard, C. C. et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J. Mol. Diagn. 16, 56\u201367 (2014).","journal-title":"J. Mol. Diagn."},{"key":"51577_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/2159-8290.CD-11-0184","volume":"2","author":"N Wagle","year":"2012","unstructured":"Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82\u201393 (2012).","journal-title":"Cancer Discov."},{"key":"51577_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","volume":"153","author":"LA Garraway","year":"2013","unstructured":"Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17\u201337 (2013).","journal-title":"Cell"},{"key":"51577_CR6","doi-asserted-by":"publisher","first-page":"111ra121","DOI":"10.1126\/scitranslmed.3003161","volume":"3","author":"S Roychowdhury","year":"2011","unstructured":"Roychowdhury, S. et al. Personalized oncology through integrative high-throughput sequencing: a Pilot Study. Sci. Transl. Med. 3, 111ra121 (2011).","journal-title":"Sci. Transl. Med."},{"key":"51577_CR7","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1038\/onc.2015.90","volume":"34","author":"H Nakagawa","year":"2015","unstructured":"Nakagawa, H., Wardell, C. P., Furuta, M., Taniguchi, H. & Fujimoto, A. Cancer whole-genome sequencing: present and future. Oncogene 34, 5943\u20135950 (2015).","journal-title":"Oncogene"},{"key":"51577_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08214-8","volume":"21","author":"Ven","year":"2021","unstructured":"Ven et al. Whole genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer 21, 488 (2021).","journal-title":"BMC Cancer"},{"key":"51577_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2021.06.018","volume":"84","author":"R Rosenquist","year":"2022","unstructured":"Rosenquist, R. et al. Clinical utility of whole-genome sequencing in precision oncology. Semin. Cancer Biol. 84, 32\u201339 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"51577_CR10","doi-asserted-by":"publisher","first-page":"e2200245","DOI":"10.1200\/PO.22.00245","volume":"6","author":"E Cuppen","year":"2022","unstructured":"Cuppen, E. et al. Implementation of whole-genome and transcriptome sequencing into clinical cancer care. JCO Precis. Oncol. 6, e2200245 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"51577_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.canlet.2012.11.025","volume":"340","author":"J Xuan","year":"2013","unstructured":"Xuan, J., Yu, Y., Qing, T., Guo, L. & Shi, L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett. 340, 284\u2013295 (2013).","journal-title":"Cancer Lett."},{"key":"51577_CR12","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1038\/srep03494","volume":"3","author":"SQ Wong","year":"2013","unstructured":"Wong, S. Q. et al. Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. Sci. Rep.-uk 3, 3494 (2013).","journal-title":"Sci. Rep.-uk"},{"key":"51577_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1373\/clinchem.2012.202390","volume":"59","author":"H Do","year":"2013","unstructured":"Do, H., Wong, S. Q., Li, J. & Dobrovic, A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin. Chem. 59, 1376\u20131383 (2013).","journal-title":"Clin. Chem."},{"key":"51577_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/gim.2017.241","volume":"20","author":"P Robbe","year":"2018","unstructured":"Robbe, P. et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. Genet. Med. 20, 1196\u20131205 (2018).","journal-title":"Genet. Med."},{"key":"51577_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.20892\/j.issn.2095-3941.2016.0004","volume":"13","author":"SP Strom","year":"2016","unstructured":"Strom, S. P. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol. Med. 13, 3\u201311 (2016).","journal-title":"Cancer Biol. Med."},{"key":"51577_CR16","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1097\/JTO.0b013e31829f691f","volume":"8","author":"X Ye","year":"2013","unstructured":"Ye, X. et al. High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact? J. Thorac. Oncol. 8, 1118\u20131120 (2013).","journal-title":"J. Thorac. Oncol."},{"key":"51577_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32041-5","volume":"13","author":"Q Guo","year":"2022","unstructured":"Guo, Q. et al. The mutational signatures of formalin fixation on the human genome. Nat. Commun. 13, 4487 (2022).","journal-title":"Nat. Commun."},{"key":"51577_CR18","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","volume":"25","author":"J Staaf","year":"2019","unstructured":"Staaf, J. et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat. Med. 25, 1526\u20131533 (2019).","journal-title":"Nat. Med."},{"key":"51577_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1369\/0022155420945050","volume":"68","author":"W Mathieson","year":"2020","unstructured":"Mathieson, W. & Thomas, G. A. Why formalin-fixed, paraffin-embedded biospecimens must be used in genomic medicine: an evidence-based review and conclusion. J. Histochem. Cytochem. 68, 543\u2013552 (2020).","journal-title":"J. Histochem. Cytochem."},{"key":"51577_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"51577_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525 (2017).","journal-title":"Nat. Med."},{"key":"51577_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751\u2013759 (2015).","journal-title":"Nat. Med."},{"key":"51577_CR23","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/ng.3683","volume":"48","author":"J-J Hao","year":"2016","unstructured":"Hao, J.-J. et al. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat. Genet. 48, 1500\u20131507 (2016).","journal-title":"Nat. Genet."},{"key":"51577_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ng.2891","volume":"46","author":"M Gerlinger","year":"2014","unstructured":"Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225\u2013233 (2014).","journal-title":"Nat. Genet."},{"key":"51577_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen, L., Martens, J. W. M., Hoeck, A. V. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 5584 (2020).","journal-title":"Nat. Commun."},{"key":"51577_CR26","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/S0140-6736(21)00673-5","volume":"398","author":"KA Fleming","year":"2021","unstructured":"Fleming, K. A. et al. The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet 398, 1997\u20132050 (2021).","journal-title":"Lancet"},{"key":"51577_CR27","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1470-2045(22)00540-X","volume":"24","author":"M Lawler","year":"2023","unstructured":"Lawler, M. et al. European Groundshot\u2014addressing Europe\u2019s cancer research challenges: a Lancet Oncology Commission. Lancet Oncol. 24, e11\u2013e56 (2023).","journal-title":"Lancet Oncol."},{"key":"51577_CR28","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(21)01895-X","volume":"398","author":"FM Knaul","year":"2021","unstructured":"Knaul, F. M. et al. The Lancet Commission on cancer and health systems: harnessing synergies to achieve solutions. Lancet 398, 1114\u20131116 (2021).","journal-title":"Lancet"},{"key":"51577_CR29","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","volume":"629","author":"JE Abraham","year":"2024","unstructured":"Abraham, J. E. et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature 629, 1142\u20131148 (2024).","journal-title":"Nature"},{"key":"51577_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354 (2016).","journal-title":"Nature"},{"key":"51577_CR31","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"51577_CR32","unstructured":"Degasperi, A. et al. Substitution mutational signatures in whole-genome\u2013sequenced cancers in the UK population. Science 376, abl9283 (2022)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51577-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51577-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T13:05:28Z","timestamp":1725455128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51577-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51577"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51577-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D., H.R.D., G.C.C.K., G.R., and S.N.-Z. hold patents or have submitted applications on clinical algorithms of mutational signatures: MMRDetect (PCT\/EP2022\/057387), HRDetect (PCT\/EP2017\/060294), clinical use of signatures (PCT\/EP2017\/060289), rearrangement signature methods (PCT\/EP2017\/060279), clinical predictor (PCT\/EP2017\/060298), and hotspots for chromosomal rearrangements (PCT\/EP2017\/060298). Z.K. is an employee of Illumina, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7731"}}